Phase 1
N=25
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Bottom Line
View on ClinicalTrials.gov: NCT03930680 ↗Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Dexrazoxane (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Arkansas
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants With 95% Reduction in Topoisomerase 2 b From Baseline |
0; 0; 0; 0; 1 | — |
Summary
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
Eligibility Criteria
Inclusion Criteria
- Women,
- Age 18-65,
- Not pregnant, Not currently breast feeding
- No current illness,
Exclusion Criteria
- Pregnancy, currently breast feeding
- Current illness,
- History of cardiac, or renal disease
Data sourced from ClinicalTrials.gov (NCT03930680). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.